28 min listen
Speeding the Delivery of CAR-T Therapies While Cutting the Cost
FromThe Bio Report
ratings:
Length:
23 minutes
Released:
Sep 24, 2020
Format:
Podcast episode
Description
CAR-T therapies are an area of great promise for improving outcomes for cancer patients, but the process of preparing cells taken from a patient and genetically modifying them is time consuming and costly. Exuma Biotech believes it can address the cost and time involved in the preparation of these products with its rapid, point-of-care platform technology. We spoke to Greg Frost, chairman and CEO Exuma Biotech, about CAR-T therapies, how its technology works, and how it is working to cut the cost, and speed the delivery of these immunotherapies to patients.
Released:
Sep 24, 2020
Format:
Podcast episode
Titles in the series (100)
How One Foundation is Getting the Biggest Bang for Its R&D Bucks: As pressure on government and corporate research budgets grow, organizations like the Multiple Myeloma Research Foundation are playing an increasingly critical role in advancing and accelerating drug development. The foundation’s efforts, including i... by The Bio Report